Missak Haigentz1, Page Moore2, Milan Bimali3, Timothy Cooley4, Joseph Sparano5, Michelle Rudek6, Lee Ratner7, David Henry8, Juan Ramos9, John Deeken10, Paul Rubinstein11, Elizabeth Chiao12. 1. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 2. CorEvitas, Waltham, MA, USA. 3. University of Arkansas for Medical Sciences, Little Rock, AK, USA. 4. Boston Medical Center, Boston, MA, USA. 5. Mount Sinai School of Medicine, New York, NY, USA. 6. Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Washington University School of Medicine, St. Louis, MO, USA. 8. Pennsylvania Hospital, Philadelphia, PA, USA. 9. University of Miami School of Medicine, Miami, FL, USA. 10. Inova Schar Cancer Institute, Fairfax, VA, USA. 11. John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA. 12. MD Anderson Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Persons living with human immunodeficiency virus are an underserved population for evidence-based cancer treatment. Paclitaxel and carboplatin (PCb) is an active regimen against a variety of solid tumors, including several seen in excess in patients with HIV infection. We performed a pilot trial to evaluate the safety of full-dose PCb in people living with human immunodeficiency virus and cancer. METHODS: Eligible patients, stratified by concurrent antiretroviral therapy (ART) that included CYP3A4 inhibitors or not, received paclitaxel (175 mg/m2) in combination with carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles. RESULTS: Sixteen evaluable patients received 64 cycles of PCb, including 6 patients treated with CYP3A4 inhibiting ART (ritonavir). The adverse event profile was consistent with the known toxicity profile of PCb, with no differences between the 2 strata. There were 4 partial responses (25%, 95% CI: 7%-52%), and overall, CD4+ lymphocyte count was similar after completion of therapy (median: 310/μL) compared with baseline values (median: 389/μL). Pharmacokinetic studies in 6 patients revealed no significant differences in Cmax or AUCinf for paclitaxel between the 2 cohorts. CONCLUSION: Full doses of PCb chemotherapy are tolerable when given concurrently with ART in people living with human immunodeficiency virus with cancer, including patients receiving CYP3A4 inhibitors. CLINICALTRIALS.GOV IDENTIFIER: NCT01249443.
BACKGROUND: Persons living with human immunodeficiency virus are an underserved population for evidence-based cancer treatment. Paclitaxel and carboplatin (PCb) is an active regimen against a variety of solid tumors, including several seen in excess in patients with HIV infection. We performed a pilot trial to evaluate the safety of full-dose PCb in people living with human immunodeficiency virus and cancer. METHODS: Eligible patients, stratified by concurrent antiretroviral therapy (ART) that included CYP3A4 inhibitors or not, received paclitaxel (175 mg/m2) in combination with carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles. RESULTS: Sixteen evaluable patients received 64 cycles of PCb, including 6 patients treated with CYP3A4 inhibiting ART (ritonavir). The adverse event profile was consistent with the known toxicity profile of PCb, with no differences between the 2 strata. There were 4 partial responses (25%, 95% CI: 7%-52%), and overall, CD4+ lymphocyte count was similar after completion of therapy (median: 310/μL) compared with baseline values (median: 389/μL). Pharmacokinetic studies in 6 patients revealed no significant differences in Cmax or AUCinf for paclitaxel between the 2 cohorts. CONCLUSION: Full doses of PCb chemotherapy are tolerable when given concurrently with ART in people living with human immunodeficiency virus with cancer, including patients receiving CYP3A4 inhibitors. CLINICALTRIALS.GOV IDENTIFIER: NCT01249443.
Authors: Michael S McLemore; Missak Haigentz; Richard V Smith; Gerard J Nuovo; Llucia Alos; Antonio Cardesa; Margaret Brandwein-Gensler Journal: Head Neck Pathol Date: 2010-03-24
Authors: Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Michelle A Rudek; Bruce J Dezube; Susan E Krown; Joseph A Sparano Journal: Cancer Chemother Pharmacol Date: 2011-01-05 Impact factor: 3.333
Authors: Erin R Gardner; Chi-Ting Liau; Zyting E Chu; William D Figg; Alex Sparreboom Journal: Rapid Commun Mass Spectrom Date: 2006 Impact factor: 2.419
Authors: Rennatus Mdodo; Emma L Frazier; Shanta R Dube; Christine L Mattson; Madeline Y Sutton; John T Brooks; Jacek Skarbinski Journal: Ann Intern Med Date: 2015-03-03 Impact factor: 25.391
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Julia L Marcus; Chun R Chao; Wendy A Leyden; Lanfang Xu; Daniel B Klein; Michael A Horberg; William J Towner; Charles P Quesenberry; Donald I Abrams; Stephen K Van Den Eeden; Michael J Silverberg Journal: J Acquir Immune Defic Syndr Date: 2014-08-15 Impact factor: 3.731